Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

1. Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials (Full text)

Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation JAMA Psychiatry Actions . 2021 Apr 20;e210620. doi: 10.1001/jamapsychiatry.2021.0620. Online ahead of print. Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials

2021 EvidenceUpdates PubMed abstract

2. Lurasidone (Latuda) - for the treatment of schizophrenia in adults and adolescents

Lurasidone (Latuda) - for the treatment of schizophrenia in adults and adolescents Final Appraisal Recommendation Advice No: 0421 – March 2021 Lurasidone (Latuda ® ) 18.5 mg, 37 mg, 74 mg film-coated tablets Submission by Sunovion Pharmaceuticals Europe Ltd Recommendation of AWMSG Lurasidone (Latuda ® ) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults and adolescents aged 13 years and over. Additional note(s): ? The above advice incorporates (...) and replaces the AWMSG recommendation for lurasidone (Latuda ® ) for the treatment of schizophrenia in adults aged 18 years and over (advice number 0115, originally published February 2015). In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 4394 and 1142), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal

2021 All Wales Medicines Strategy Group

3. Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia

Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia - Repository of AIHTA GmbH English | Browse - - - Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia Gassner, L. and Mayer-Ferbas, J. (2020): Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia (...) , Depression, Insomnia and Schizophrenia. HTA-Projektbericht 133. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 1MB Abstract Introduction: Music therapy is an expression promoting, scientific-artistic-creative and independent form of treatment and aims at maintaining, restoring, and furthering physical, emotional, and mental health. This systematic review aims at assessing the effectiveness of music therapy for the treatment of autism spectrum disorder, dementia

2020 Austrian Institute of Health Technology Assessment

4. Assessing the efficacy and feasibility of providing metacognitive training for patients with schizophrenia by mental health nurses: A randomized controlled trial

Assessing the efficacy and feasibility of providing metacognitive training for patients with schizophrenia by mental health nurses: A randomized controlled trial Assessing the efficacy and feasibility of providing metacognitive training for patients with schizophrenia by mental health nurses: A randomized controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Actions . 2020 Nov 22. doi: 10.1111/jan.14627. Online ahead of print. Assessing the efficacy and feasibility of providing metacognitive training for patients with schizophrenia by mental health nurses: A randomized controlled trial , , , , , Affiliations Expand Affiliations 1 University of Évora, Évora, Portugal. 2 Comprehensive Health Research Centre (CHRC), Évora, Portugal. 3 Universitat Rovira and Virgili, Tarragona, Spain. 4 School of Nursing of Porto, Porto, Portugal. 5 NursID - Innovation

2020 EvidenceUpdates

5. The Impacts of Parental Schizophrenia on the Psychosocial Well-Being of Offspring: A Systematic Review (Full text)

The Impacts of Parental Schizophrenia on the Psychosocial Well-Being of Offspring: A Systematic Review The Impacts of Parental Schizophrenia on the Psychosocial Well-Being of Offspring: A Systematic Review | IntechOpen Submit Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD (...) access peer-reviewed chapter The Impacts of Parental Schizophrenia on the Psychosocial Well-Being of Offspring: A Systematic Review By Sabreena Hussain Submitted: November 26th 2019 Reviewed: February 7th 2020 Published: April 28th 2020 DOI: 10.5772/intechopen.91658 > > Downloaded: 162 Edited by Floriana Irtelli, Federico Durbano and Simon George Taukeni 1. Introduction Schizophrenia is a type of ‘psychosis’ which causes individuals to experience distressing symptoms [ ] such as the lack of ability

2020 Quality of Life - Biopsychosocial Perspectives PubMed abstract

6. Semantic memory impairment across the schizophrenia continuum: a meta-analysis of category fluency performance (Full text)

Semantic memory impairment across the schizophrenia continuum: a meta-analysis of category fluency performance Validate User We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your content. Could not validate captcha. Please try again. Take me to my Content

2020 Schizophrenia Bulletin Open PubMed abstract

7. Efficacy of psychological treatments for patients with schizophrenia and relevant negative symptoms: A meta-analysis (Full text)

Efficacy of psychological treatments for patients with schizophrenia and relevant negative symptoms: A meta-analysis Efficacy of Psychological Treatments for Patients With Schizophrenia and Relevant Negative Symptoms: A Meta-Analysis| Clinical Psychology in Europe Quick jump to page content | Search Published at 30. September 2020 Issue: Section: Systematic Reviews and Meta-analyses Keywords: schizophrenia and psychosis negative symptoms psychotherapy nonpharmacological treatment meta-analysis (...) Share: Riehle, M., Böhl, M. C., Pillny, M., & Lincoln, T. M. (2020). Efficacy of Psychological Treatments for Patients With Schizophrenia and Relevant Negative Symptoms: A Meta-Analysis. Clinical Psychology in Europe , 2 (3), 1-23. https://doi.org/10.32872/cpe.v2i3.2899 More Citation Formats Download Citation This work is licensed under a PlumX Dimensions Views: Total Abstract PDF HTML XML 1005 601 338 55 11 Downloads: Download data is not yet available. Riehle M., Böhl M. C., Pillny M., Lincoln T

2020 Clinical Psychology in Europe PubMed abstract

8. Maintenance treatment with antipsychotic drugs for schizophrenia. (Abstract)

Maintenance treatment with antipsychotic drugs for schizophrenia. The symptoms and signs of schizophrenia have been linked to high levels of dopamine in specific areas of the brain (limbic system). Antipsychotic drugs block the transmission of dopamine in the brain and reduce the acute symptoms of the disorder. An original version of the current review, published in 2012, examined whether antipsychotic drugs are also effective for relapse prevention. This is the updated version of the aforesaid (...) review.To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents.We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (12 November 2008, 10 October 2017, 3 July 2018, 11 September 2019).We included all randomised trials comparing maintenance treatment with antipsychotic drugs and placebo for people with schizophrenia or schizophrenia-like psychoses.We extracted data

2020 Cochrane

9. The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis (Full text)

The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints (...) . The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The genome-wide supported CACNA1C gene polymorphisms and the risk of schizophrenia: an updated meta-analysis Yongping Liu, Xue Wu, Xi Xia, Jun Yao, Bao-jie Wang Yongping Liu China Medical University Xue Wu China Medical University Xi Xia China Medical University Jun Yao China Medical University

2020 Research Square PubMed abstract

10. Paliperidone - maintenance treatment of schizophrenia

Paliperidone - maintenance treatment of schizophrenia Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/277302/2020 EMEA/H/C/005486 Paliperidone Janssen-Cilag International (...) (paliperidone) An overview of Paliperidone Janssen-Cilag International and why it is authorised in the EU What is Paliperidone Janssen-Cilag International and what is it used for? Paliperidone Janssen-Cilag International is an antipsychotic medicine used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with paliperidone or risperidone. Some patients whose symptoms have not yet been stabilised may still be given Paliperidone Janssen- Cilag

2020 European Medicines Agency - EPARs

11. eHealth tools for assessing psychomotor activity in schizophrenia: a systematic review (Full text)

focusing on schizophrenia diagnosis. The following search terms were used (in any field): ((ehealth OR mhealth OR technology OR actigraph OR phone OR app OR virtual reality OR video game OR videogame OR wearables OR computer) AND (psychomotor OR movement OR motor OR mobility OR physical activity) AND (schizophrenia OR psychosis OR psychotic OR schizophrenic)). The references of included studies were also screened. Study selection process The publications were assessed independently by two researchers (...) eHealth tools for assessing psychomotor activity in schizophrenia: a systematic review eHealth tools for assessing psychomotor activity in schizophrenia: a systematic review Services on Demand Journal Article Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 1516-4446 On-line version ISSN 1809-452X Braz. J. Psychiatry, ahead of print Epub June 15, 2020 REVIEW ARTICLE eHealth tools for assessing psychomotor activity in schizophrenia: a systematic review Rosa

2020 Brazilian Journal of Psychiatry PubMed abstract

12. Avatar Therapy for people with schizophrenia or related disorders. (Abstract)

Avatar Therapy for people with schizophrenia or related disorders. Many people with schizophrenia do not achieve satisfactory improvements in their mental state, particularly the symptom of hearing voices (hallucinations), with medical treatment.To examine the effects of Avatar Therapy for people with schizophrenia or related disorders.In December 2016, November 2018 and April 2019, the Cochrane Schizophrenia Group's Study-Based Register of Trials (including registries of clinical trials (...) ) was searched, review authors checked references of all identified relevant reports to identify more studies and contacted authors of trials for additional information.All randomised clinical trials focusing on Avatar Therapy for people with schizophrenia or related disorders.We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and 95% confidence intervals (CI), on an intention-to-treat basis. For continuous data, we estimated the mean difference (MD) between groups and 95

2020 Cochrane

13. Pharmacotherapy for smoking cessation in schizophrenia: a systematic review. (Abstract)

Pharmacotherapy for smoking cessation in schizophrenia: a systematic review. Introduction: Rates of tobacco smoking are high in people with schizophrenia with greater difficulty of quitting smoking compared to the general population, which also relate to the increased cardiovascular and cancer risks in this co-occurring disorder. Therefore, effective smoking cessation pharmacotherapies addressing tobacco co-morbidity are imperative.Areas covered: In this review, the authors performed (...) an extensive systematic electronic literature review examining the efficacy and safety of first-line pharmacotherapies for smoking cessation, including varenicline, sustained-release bupropion, and nicotine replacement therapies (NRT) using continuous abstinence rates over 10-12-week periods in smokers with schizophrenia. Twelve trials reporting smoking cessation outcomes using interventions in schizophrenia were included and risk ratio (RR) was used.Expert opinion: Our findings support the efficacy

2020 Expert opinion on pharmacotherapy

14. Relationship of poor insight to neurocognition, social cognition, and psychiatric symptoms in schizophrenia: A meta-analysis. (Abstract)

Relationship of poor insight to neurocognition, social cognition, and psychiatric symptoms in schizophrenia: A meta-analysis. Poor insight (unawareness) about having a mental disorder is considered to be a core feature of the disorder. Further, poor insight has been associated with another core feature of schizophrenia, neurocognitive deficits. However, previous meta-analyses have shown that poor insight is more strongly related to positive symptoms and social cognition than to neurocognitive (...) functioning.A meta-analysis of 123 studies of schizophrenia patients (combined n = 14,932) was conducted to determine the magnitude of the relationship between poor insight and neurocognition, social cognition, and positive symptoms, as well as negative symptoms, disorganization, and depression. The neurocognitive constructs were defined empirically using dimensions identified by the MATRICS initiative.Meta-analytic findings showed that relationships were weak between poor insight and the six neurocognitive

2020 Schizophrenia Research

15. Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. (Abstract)

Vitamin D deficiency and Schizophrenia in Adults: A Systematic Review and Meta-analysis of Observational Studies. Schizophrenia is a heterogeneous disorder in which there is an interaction between genetic and environmental factors. Accumulating data show that there may be an association between vitamin D deficiency and schizophrenia. We conducted an updated meta-analysis to investigate the relationship between schizophrenia and blood vitamin D level. All published observational articles have (...) been searched from five databases until September 2019. In total, 36 articles with a total of 12528 participants were included in this study. Patients with schizophrenia have significantly lower levels of vitamin D than controls. The subgroup analyses based on study design, hospitalization status, quality score, type of biomarker [25-hydroxyvitamin D or 25-hydroxyvitamin D3], and the country did not explain between-study heterogeneity; however, meta-regression on match factors indicted that match

2020 Psychiatry research

16. Neural changes following cognitive remediation therapy for schizophrenia. (Full text)

Neural changes following cognitive remediation therapy for schizophrenia. Patients with schizophrenia experience cognitive impairments that relate to poorer social functioning even after amelioration of positive symptoms. Pharmacological treatment and cognitive remediation are the two important therapeutic approaches for cognitive impairment in schizophrenia. Cognitive remediation therapy (CRT) for schizophrenia improves cognitive functioning and induces neuroplasticity, but different (...) between the prefrontal cortex and temporal regions. Two studies have reported that CRT induces changes in gray matter volume in the hippocampus. Further, one study observed that patients who had received CRT had elevated fractional anisotropy in the basal ganglia. We conclude that neuroimaging studies assessing CRT in patients with schizophrenia showed functional, structural, and connectivity changes that were positively correlated with cognitive improvements despite heterogeneous CRT approaches

2020 Psychiatry and clinical neurosciences PubMed abstract

17. Retinal Changes in Schizophrenia: A Systematic Review and Meta-analysis Based on Individual Participant Data. (Full text)

Retinal Changes in Schizophrenia: A Systematic Review and Meta-analysis Based on Individual Participant Data. Retinal assessment has indicated the presence of neuronal loss in neurodegenerative disorders, but its role in schizophrenia remains unclear. We sought to synthesize the available evidence considering 3 noninvasive modalities: optical coherence tomography, electroretinography, and fundus photography, and examine their diagnostic accuracy based on unpublished individual participant data (...) was registered with PROSPERO, number CRD42018109344.Pooled mean differences of peripapillary retinal nerve fiber layer thickness in micrometer between 694 eyes of 432 schizophrenia patients and 609 eyes of 358 controls, from 11 case-control studies, with corresponding 95% confidence intervals (CIs) by quadrant were the following: -4.55, 95% CI: -8.28, -0.82 (superior); -6.25, 95% CI: -9.46, -3.04 (inferior); -3.18, 95% CI: -5.04, -1.31 (nasal); and -2.7, 95% CI: -4.35, -1.04 (temporal). Diagnostic accuracy

2020 Schizophrenia bulletin PubMed abstract

18. Breast Cancer Screening in Women With Schizophrenia: A Systematic Review and Meta-Analysis. (Abstract)

Breast Cancer Screening in Women With Schizophrenia: A Systematic Review and Meta-Analysis. Women with schizophrenia appear to receive breast cancer diagnoses at later stages of the disease compared with the general population. To study this disparity, this report reviewed and quantified the differences in rates of mammography screening for women with schizophrenia and other psychotic disorders compared with the general population.A systematic literature search was conducted in PubMed, Embase (...) , Web of Science, and PsycINFO databases. Each database was searched from inception to September 14, 2018. The search strategy included search terms for breast cancer, mammography, schizophrenia, and psychosis. Two reviewers independently screened and evaluated eligible studies. The main outcome measure was the rate of mammography screening among women with schizophrenia and psychotic disorders versus a comparable population of women without these diagnoses. Preferred Reporting Items for Systematic

2020 Psychiatric services (Washington, D.C.)

19. Altered Peripheral Blood Compounds in Drug-Naïve First-Episode Patients With Either Schizophrenia or Major Depressive Disorder, A Meta-Analysis. (Full text)

Altered Peripheral Blood Compounds in Drug-Naïve First-Episode Patients With Either Schizophrenia or Major Depressive Disorder, A Meta-Analysis. Schizophrenia and major depressive disorder (MDD) are associated with increased risks of immunologic disease and metabolic syndrome. It is unclear to what extent growth, immune or glucose dysregulations are similarly present in these disorders without the influence of treatment or chronicity.To conduct a meta-analysis investigating whether (...) there are altered peripheral growth, immune or glucose metabolism compounds in drug-naïve first-episode patients with schizophrenia or MDD compared with controls.Case-control studies reporting compound measures in drug-naïve first-episode patients with schizophrenia or MDD compared with controls in the Embase, PubMed and PsycINFO databases.Two independent authors extracted data for a random-effects meta-analysis.Peripheral growth, immune or glucose metabolism compounds in schizophrenia or MDD compared

2020 Brain, behavior, and immunity PubMed abstract

20. Hypothalamic-pituitary-adrenal axis-related genes and cognition in major mood disorders and schizophrenia: a systematic review. (Abstract)

Hypothalamic-pituitary-adrenal axis-related genes and cognition in major mood disorders and schizophrenia: a systematic review. Hypothalamic-pituitary-adrenal (HPA) axis dysregulation and cognitive deficits are two well-characterized endophenotypes present in different serious mental illnesses (SMIs), including major depressive disorder, bipolar disorder and schizophrenia. Our aim was to study the influence of genetic and epigenetic variations in HPA axis-related genes on cognitive performance (...) in clinical samples, including patients with major mood disorders and schizophrenia. A systematic search was performed using PubMed (Medline), PsycINFO and Scopus databases. The systematic review identified 12 studies dealing with HPA-related genes and cognition in samples including patients with SMIs, focusing on single nucleotide polymorphism (SNP) variants, while no studies analysing epigenetic variations were found. The results suggest different and specific effects on the cognitive performance of SNP

2020 Progress in neuro-psychopharmacology & biological psychiatry